López-Cañizares Ashley, da Cruz Natasha Ferreira Santos, Al-Khersan Hasenin, Berrocal Audina Maria
Bascom Palmer Eye Institute, Miami, FL, USA.
J Vitreoretin Dis. 2023 May 17;7(5):455-458. doi: 10.1177/24741264231173206. eCollection 2023 Sep-Oct.
To present 2 cases of premature newborns with hyperbilirubinemia and retinopathy of prematurity (ROP) who could not be examined properly to assess for disease progression because of vitreous opacification in the setting of an icteric vitreous and frail health status. The cases and their findings were analyzed. Given the sickness of the neonates and examination difficulty, intravitreal bevacizumab was administered in both eyes to prevent disease progression. During subsequent examinations, the patients remained stable until discharge from the neonatal intensive care unit and were followed in the outpatient clinic without complication. The ROP and vitreous opacification in our cases were thought to be caused by hyperbilirubinemia. Because of vitreous opacification, these patients could not be properly examined for ROP. Treatment with an intravitreal antivascular endothelial growth factor injection might be considered to delay disease development until the newborn is healthier and able to be examined.
介绍2例患有高胆红素血症和早产儿视网膜病变(ROP)的早产儿,由于黄疸性玻璃体混浊和健康状况脆弱,无法进行适当检查以评估疾病进展。对这些病例及其检查结果进行了分析。鉴于新生儿病情较重且检查困难,对双眼均给予玻璃体内注射贝伐单抗以预防疾病进展。在随后的检查中,患者病情保持稳定,直至从新生儿重症监护病房出院,并在门诊随访,未出现并发症。我们病例中的ROP和玻璃体混浊被认为是由高胆红素血症引起的。由于玻璃体混浊,这些患者无法对ROP进行适当检查。可以考虑玻璃体内注射抗血管内皮生长因子进行治疗,以延缓疾病发展,直到新生儿身体更健康且能够接受检查。